On December 5, 2023, the Board of Directors of Absci Corporation, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Professor Sir Menelas Pangalos to the Board, effective January 1, 2024. Simultaneously with the effectiveness of Sir Pangalos?s appointment, the size of the Board will be fixed at seven directors and a second director position will be added among the Class II directors. Sir Pangalos will serve as a Class II director of the Company, to hold office until the Company?s 2026 annual meeting of stockholders or until his earlier resignation, death, or removal.

Upon the effectiveness of his appointment, Sir Pangalos was also appointed to serve on the Compensation Committee of the Board. Sir Pangalos currently serves as Executive Vice-President, R&D BioPharmaceuticals at AstraZeneca.